login
  Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 

US PYTHAGORAS data shows Aorfix is promising for patients with extremely tortuous anatomy


Tuesday, 12 Jun 2012 10:27
AorFix
AorFix


Lombard today announced the high angle clinical data results from the US PYTHAGORAS trial of its endovascular stent graft Aorfix. Data suggest that Aorfix has the potential to provide a less invasive treatment option for abdominal aortic aneurysm patients with highly angulated neck anatomy.


The unique data set, presented at the Society of Vascular Surgery (SVS) Annual Meeting (7–9 June, USA) by Mark Fillinger of Dartmouth Hitchcock Medical Centre, New Hampshire, USA, featured results from the world’s first and largest multicentre EVAR clinical trial studying patients with angles greater than 60 degrees.

Two hundred and five patients were recruited in the trial and the data resulted from 143 patients with highly-angulated aortic necks (angles between 60 and 110 degrees). Treatment of this patient group is not indicated in any stent grafts currently available in the USA.

The data presented showed that Aorfix performed well in extreme aortic neck angulations. Outcomes such as freedom from major adverse events (MAEs, as defined by the SVS) at 30 days and 365 days, were significantly lower than in patients undergoing open surgical repair (81.1% vs. 56.4%, p<0.0001 and 75.5% vs. 54.5%, p<0.0001 respectively). Although not tested in this trial, Fillinger noted that the outcomes were similar to EVAR trials of other stent grafts in much less severe anatomy.

The PYTHAGORAS trial’s results were achieved despite the inclusion of patients with predictors of worse short and long-term outcomes such as:

  • age (75.4+/-8 years vs. 69.2 +/-7 years, p=0.001);

  • proportion of female patients (35% vs. 20%, p=0.015);

  • congestive heart failure (14% vs. 4%, p=0.029); and

  • high neck angles (83+/-15 degrees, compared to SVS control group: 48+/-22 degrees, p<0.05)

“Aorfix has produced promising results in this extremely challenging patient group with high neck angles whose only treatment option currently is open surgical repair. Once available in the US, Aorfix should provide clinicians with a versatile option for treating patients with challenging abdominal aortic aneurysm anatomy, significantly expanding our ability to treat this condition in a minimally invasive fashion,”Fillinger said.

Simon Hubbert, chief executive of Lombard Medical said, “We are very pleased with the US PYTHAGORAS data, further evidence that Aorfix is an excellent treatment option for patients with extremely tortuous anatomy and who previously had no endovascular options. Our work supporting the US approval process for Aorfix is on track and we continue to anticipate US approval by the end of the year.”

Aorfix is currently commercially available in Europe and Lombard expects to launch the stent graft in the USA later this year, subject to FDA approval.




Add New Comment

Most popular


Live from VEITH 2014: SUPERB results show 94% freedom from reintervention with nominal deployment of Supera at three years
Wednesday, 19 Nov 2014
Three-year follow-up results of patients treated with the Supera stent show that nominal deployment or slight compression of the device delivers the best outcomes in terms of durability, and that ... Live from VEITH 2014: SUPERB results show 94% freedom from reintervention with nominal deployment of Supera at three years

New deep vein thrombosis guidelines: What you need to know
Thursday, 23 Oct 2014
Suresh Vedantham spoke to Interventional News on the latest from the paper “Quality improvement guidelines for the treatment of lower-extremity deep vein thrombosis with use of endovascular thrombus ... New deep vein thrombosis guidelines: What you need to know

Bioresorbable scaffolds can produce comparable acute results to metal stents
Tuesday, 04 Nov 2014
Speaking at the Asian Society for Vascular Surgery meeting (5–7 September, Hong Kong, China), Andrew Holden commented that studies indicate that bioresorbable scaffolds can produce comparable acute ... Bioresorbable scaffolds can produce comparable acute results to metal stents

Features


Stentoplasty: An “exciting frontier” in spinal augmentation
Thursday, 27 Nov 2014
Stentoplasty, or vertebral body stenting, represents the next step in the evolution of cement spinal augmentation where a stent is placed within the vertebral body followed by infusion of cement. Stentoplasty: An “exciting frontier” in spinal augmentation

CO2 angiography should be more widely used
Thursday, 27 Nov 2014
CO2 angiography can decrease both morbidity and mortality for patients, in certain clinical scenarios. For those driven by economics, the cost of 100cc of CO2 is approximately three cents. Its use is ... CO2 angiography should be more widely used

Profiles


Gao-Jun Teng
Thursday, 11 Dec 2014
In the future, will interventional radiology be a subspecialty of radiology, or surgery? asks Gao-J... Gao-Jun Teng

José Ignacio Bilbao Jaureguízar
Wednesday, 08 Oct 2014
“No matter what their future orientation, interventional radiologists involved in interventional ... José Ignacio Bilbao Jaureguízar

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions